Replies to post #24377 on Biotech Values

[DewDiligence]

Re: CVM

>Besides curing cancer and HIV, CVM now has a drug, in animal testing, of course, that can cure the Avian flu virus, of course.<

LOL—Biowatch and I have mused on this board that CVM has a lot in common with HEB. Maybe more in common than I thought.

>Who wrote that this was a promising company?<

The CVM thread today began with message #24343, but it was an innocent post and I don’t think we should be unduly critical.

[DewDiligence]

CVM – Would a legit company
ever issue a PR like this one?

http://biz.yahoo.com/prnews/060620/dctu013.html?.v=60

>>
CEL-SCI Corporation Releases Letter to Shareholders

Tuesday June 20, 9:00 am ET

VIENNA, Va., June 20 /PRNewswire-FirstCall/ -- The following letter is being released by CEL-SCI CORPORATION (Amex: CVM ) to its shareholders from Geert Kersten, Chief Executive Officer:

The stock market is worried about inflation and biotech stocks are being knocked down. Does that make sense? Are patients less interested in saving their lives because the price of a gallon of gas is now over $3? With inflation fears reducing the attractiveness of many stocks, biotech stocks should get the attention of investors as an alternate place to invest. Certainly the pharmaceutical companies are taking advantage of the lack of investor interest in biotech stocks. During the past months they have acquired many biotechnology companies to the tune of billions of dollars, e.g., AstraZeneca's purchase of Cambridge Antibody Technology for $1.3 billion. Our own company's stock, CEL-SCI Corporation (Amex: CVM ), has been pulled down with the general market even though we recently presented excellent long-term survival data with our cancer drug Multikine®. Seeing such a disconnect between real data and market valuation, I have just bought another 87,600 shares of CEL-SCI in the open market. The value proposition was simply too good to pass up.

During the past 12 months CEL-SCI has achieved great milestones. We received the Canadian go-ahead for a Phase III clinical trial with our cancer drug Multikine, we received a key patent on Multikine giving us another 18 years of market exclusivity, and we had Multikine's mechanism of action published in a leading cancer journal. Most recently we were able to announce a 33-40% improvement in patient survival after long-term follow-up (3 1/2 years) in our key Phase II study with Multikine.

In my opinion, we have set this Company up to enter its Phase III cancer trial with a great deal of risk mitigation and an enormous upside. We have validated the manufacturing process, we have conducted many Phase II studies to determine the right dose to administer, we have waited for long-term Phase II data showing a very significant increase in survival, and the Phase II treatment regimen showing the increase in survival is the same as the one we will be using in our Phase III trial. Clearly the market we are pursuing is very large, constituting 5-6% of all cancer patients. Since we still have all of the major markets available for partnering, we are seeing interest in Multikine from pharmaceutical companies.

I often find it helpful to summarize complicated issues in a more simplistic manner. Therefore I have compiled a list of the key reasons as to why I would use Multikine if I were a cancer patient:
1) It is non-toxic and treatment takes only 3 weeks.
2) 12% of the patients in the key Phase II study had no remaining tumor after Multikine treatment.
3) After treatment with Multikine the average tumor reduction in this study was about 50%, before the standard treatments even started. I like the idea of the enemy's army being 50% reduced before the fight even begins.
4) Our publication in the Laryngoscope has shown that pre-treatment with Multikine should significantly enhance the effectiveness of follow-on radiation and chemotherapy.
5) We showed a substantial increase in survival in our key Phase II study.
6) Multikine pretreatment does not preclude any other therapy.

My feeling is that I would have a lot to gain and nothing to lose by taking Multikine. I believe that many others will feel the same and, it is for this reason that I believe that Multikine will some day be added to many of the current cancer therapies.
<<

[DewDiligence]

As noted in #msg-41436720, write-ups from BioMedReports.com
are allowed on this board only if they are for comic relief. This
PR, which pertains to the longstanding scam company CVM, is
indeed for comic relief.

http://finance.yahoo.com/news/CELSCIs-H1N1-Treatment-and-iw-1901294370.html?x=0&.v=1

›CEL-SCI's H1N1 Treatment and Vaccines Getting Some Attention From U.S. Government

Press Release
Source: BioMedReports
Tuesday September 15, 2009, 9:18 am EDT

PASADENA, CA--(Marketwire - 09/15/09) - BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors [uh huh], has issued a special investigative report on CEL-SCI Corporation (AMEX: CVM ).

According to the report, the company had been in discussions over the past several days with multiple government groups interested in expediting CEL-SCI's H1N1 efforts. [In other words, BioMedReports itself is the source of this speculation—LMAO.]

Contacted about the developments, CEL-SCI's CEO Geert Kersten made it clear that he was not able to comment on the nature or scope of any of these meetings.

When asked about recent SEC filings that shows that the company has been working not only influenza vaccines using their patented L.E.A.P.S.(TM) technology, but also some treatment options for already infected patients, Kersten shed more light on the situation:

"Everything here is done by collaboration. That's the idea of the team. It may have been someone's comment leading to the input of others and that took us down the road of the mutated virus and then we said, 'Well, if we can work on the mutated virus, who is actually addressing the issue of all those people lying in an ICU today, fighting for their lives for a week or ten days?' And then we figured out that using the same approach we ought to be able to help them improve their chances of survival.

"Somewhere along the way, it was like a Eureka moment," explains Kersten. "We've got to help these people. Everybody's focus is on vaccines and they're having all kinds of problems with the vaccines, but there has to be someone working to help these patients who have a high likelihood of death. That's how we got to that.

"With L.E.A.P.S.(TM) we can control in advance and determine, almost by design, how the immune system will process the epitope and therefore we know what kind of immune response we will get -- whether cellular or humoral. By doing that, you can -- we feel -- have significant impact on these people's chances of survival."

The complete special report authored by BioMedReport's M.E. Garza is available now at:

http://biomedreports.com/articles/most-popular/9421-cloak-and-dagger-developments-at-cel-sci-amexcvm.html

About BiomedReports.Com

BioMedReports.com is a news portal covering the biomedical news and financial sector. It features its own blog, discussion forum, stock research reports, news feeds, videos, press release capability, stock commentaries, and other unique content -- including FDA and Clinical Trial Calendars. For more biomedical sector and investment news, go to www.BioMedReports.com.‹

[DewDiligence]

Bladerunner, this one’s for you:

http://www.thestreet.com/print/story/10678206.html

LMAO

[DewDiligence]

If anyone didn’t know CVM is a scam, this paragraph from Thursday’s PR should have removed all doubt:

http://finance.yahoo.com/news/CELSCI-Corporation-Releases-bw-3138458281.html?x=0&.v=1

During the past 20 plus years our Company endured many challenges. Management funded the company when needed and dedicated employees worked without paychecks or with reduced paychecks. Then there were the games of greed… During the last financial crisis hedge funds tried to take the company over, and more…. We believe that the results of the Phase III study will ultimately dictate our success, and we further believe that, given the huge amount of value our new cancer therapy would create, the games of greed will continue during the Phase III study. We are already seeing lies being spread on the internet about our study and our Company. People claim to know that the study was halted, that production of Multikine was halted, that patients were having problems, all falsehoods designed to influence others. We are dedicated to proving that Multikine works and that is our answer to those lies.

LMAO

[DewDiligence]

Beware of biotech companies who issue folksy letters to shareholders from the CEO; CVM is a case in point:

http://finance.yahoo.com/news/CEL-SCI-Corporation-Releases-bw-4123257218.html?x=0

During 2011, we made great operational progress in bringing our investigational cancer drug Multikine® (Leukocyte Interleukin, Injection) closer to market. Our Phase III clinical trial for head and neck cancer, which is designed to prove to the most rigorous standards that Multikine works, was launched in dozens of hospitals located in eight countries on three continents. This trial is the largest head and neck cancer trial in the world. All of us at CEL-SCI are very proud of this major accomplishment.

What a crock.

[DewDiligence]

Geert Kersten feels good about what CVM accomplished in fiscal-year 2012:

http://finance.yahoo.com/news/cel-sci-corporation-announces-fiscal-211500750.html

LMAO

[DewDiligence]

Yet another, “Dear CEL-SCI shareholders” letter from the CEO:

https://www.businesswire.com/news/home/20180821005193/en

Still scamming after all these years!

[DewDiligence]

CVM issues folksy shareholder letter to hoodwink unsuspecting investors—for the umpteenth time:

https://finance.yahoo.com/news/cel-sci-corporation-issues-letter-201900669.html

This letter could serve as a prototype for the genre.

Everyone should read the second paragraph of the message I'm replying to, which was posted fourteen years ago.